Evidence map›Paper›PMID 33972393›Full record

ArticleMolecular and cellular biology2021

Nuclear Lamin A/C Expression Is a Key Determinant of Paclitaxel Sensitivity.

Elizabeth R Smith, Justin Leal, Celina Amaya, Bing Li, Xiang-Xi Xu

Open access · greenAbstract read
In one paragraph

Article in Molecular and cellular biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 38 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Micronuclei: origins, assays, mechanisms, diseases and treatments.Signal transduction and targeted therapy · 2026
    Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Cell death in cancer chemotherapy using taxanes.Frontiers in pharmacology · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Elizabeth R SmithSylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida, USA.
Justin LealDepartment of Radiation Oncology, University of Miami Miller School of Medicine, Miami, Florida, USA.
Celina AmayaDepartment of Radiation Oncology, University of Miami Miller School of Medicine, Miami, Florida, USA.
Bing LiSylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida, USA.
Xiang-Xi XuSylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida, USA.
University of Miami · US

Funding

Ovarian Cancer: Epithelial DedifferentiationR01CA079716 · NCI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI XU, XIANGXI MIKE · 1999 to 2015
$4.8M
Gonadotropins &Cox-2 in Ovarian Cancer PreventionR01CA099471 · NCI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI XU, XIANGXI MIKE · 2003 to 2014
$4.0M
Epithelial Positioning Organization and Ovarian CancerR01CA095071 · NCI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI XU, XIANGXI MIKE · 2002 to 2010
$3.2M
Ovarian Epithelial Cancer Progenitor Cell PopulationR01CA230916 · NCI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI XU, XIANGXI MIKE · 2018 to 2022
$2.1M
Mechanism of MAPK Cytoplasmic Retention in Differentiation of ES CellsR03HD071244 · NICHD · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI SMITH, ELIZABETH R · 2012 to 2013
$149k
NCI NIH HHS R01 CA079716NCI NIH HHS R01 CA095071NCI NIH HHS R01 CA099471NCI NIH HHS R01 CA230916NICHD NIH HHS R03 HD071244
6 · The paper itself

Abstract

Paclitaxel is a key member of the Taxane (paclitaxel [originally named taxol], docetaxel/Taxotere) family of successful drugs used in the current treatment of several solid tumors, including ovarian cancer. The molecular target of paclitaxel has been identified as tubulin, and paclitaxel binding alters the dynamics and thus stabilizes microtubule bundles. Traditionally, the anticancer mechanism of paclitaxel has been thought to originate from its interfering with the role of microtubules in mitosis, resulting in mitotic arrest and subsequent apoptosis. However, recent evidence suggests that paclitaxel operates in cancer therapies via an as-yet-undefined mechanism rather than as a mitotic inhibitor. We found that paclitaxel caused a striking break up of nuclei (referred to as multimicronucleation) in malignant ovarian cancer cells but not in normal cells, and susceptibility to undergo nuclear fragmentation and cell death correlated with a reduction in nuclear lamina proteins, lamin A/C. Lamin A/C proteins are commonly lost, reduced, or heterogeneously expressed in ovarian cancer, accounting for the aberration of nuclear shape in malignant cells. Mouse ovarian epithelial cells isolated from lamin A/C-null mice were highly sensitive to paclitaxel and underwent nuclear breakage, compared to control wild-type cells. Forced overexpression of lamin A/C led to resistance to paclitaxel-induced nuclear breakage in cancer cells. Additionally, paclitaxel-induced multimicronucleation occurred independently of cell division that was achieved by either the withdrawal of serum or the addition of mitotic inhibitors. These results provide a new understanding for the mitotis-independent mechanism for paclitaxel killing of cancer cells, where paclitaxel induces nuclear breakage in malignant cancer cells that have a malleable nucleus but not in normal cells that have a stiffer nuclear envelope. As such, we identify that reduced nuclear lamin A/C protein levels correlate with nuclear shape deformation and are a key determinant of paclitaxel sensitivity of cancer cells.

Indexed as

AnimalsAntimitotic AgentsApoptosisCell Line, TumorDrug Resistance, NeoplasmFemaleHumansLamin Type AMice, TransgenicMicrotubulesMitosisOvarian NeoplasmsPaclitaxelTubulinAntimitotic AgentsLamin Type APaclitaxelTubulindrug resistancelamin A/Cmicronucleimicrotubulemitosismitotic inhibitormultimicronucleationnuclear envelopenuclear laminaovarian cancerpaclitaxel

Identifiers

PMID33972393
PMCPMC8224231
OpenAlexW3162869778

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.